PT-141 (10 mg) + Melanotan II (10 mg) Stack

PT-141 (10 mg) + Melanotan

PT-141 is dosed at 750 mcg–1.75 mg daily via subcutaneous injection in educational protocols. A 10 mg reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.

PT-141 and Melanotan II are included here as part of a general product information guide. This content is not intended as medical advice, treatment guidance, dosage guidance, or usage instruction. For product-specific details, availability, or additional information, please contact us on Telegram.

Educational guide for reconstitution and daily dosing

PT-141 (Bremelanotide) — On-Demand Protocol (3 mL = ~3.33 mg/mL)

Route: Subcutaneous injection (abdomen or thigh). Frequency: On-demand, at least 45 minutes before anticipated sexual activity; no more than 1 dose per 24 hours and ≤8 doses per month.

PhaseDose (mcg)Units (per injection) (mL)
Initial / Titration500–750 mcg15–22 units (0.15–0.22 mL)
Standard1000–1500 mcg30–45 units (0.30–0.45 mL)
Full / FDA-Approved1750 mcg (1.75 mg)52 units (0.52 mL)

Titration: Start at a lower dose (500–750 mcg) and increase as tolerated. Nausea is common with initial use and typically diminishes with subsequent doses.

Melanotan II — Daily Protocol (3 mL = ~3.33 mg/mL)

Route: Subcutaneous injection (abdomen or thigh). Frequency: Once daily during loading phase; reduced frequency for maintenance.

Route: Subcutaneous injection | Frequency: Once daily or split twice weekly for TB-500 loading

WeekDaily Dose (mcg)Units (per injection) (mL)
Week 1250 mcg7.5 units (0.075 mL)*
Week 2500 mcg15 units (0.15 mL)
Weeks 3–4750 mcg22 units (0.22 mL)
Weeks 5+ (Loading)1000 mcg30 units (0.30 mL)
Maintenance500–1000 mcg (2–3×/week)15–30 units (0.15–0.30 mL)

*For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.

Titration: Begin at 250 mcg and increase by 250 mcg every 5–7 days as tolerated. Nausea and flushing are common initially and typically subside with continued use.

Product Information Notes (Both Peptides)

Important: This guide is for <b>educational purposes only</b> and is not medical advice. For research use only. Not for human consumption.

Plan based on general product information for educational and research reference only. For product-specific details, preparation information, or availability, please contact us on Telegram.

Summary of both product information guides.

Key product information for educational and research reference only.

Proper storage information is provided for general educational and research reference only.

Practical product information for general educational and research reference only.

PT-141 and Melanotan II information is provided for general educational and research reference only. This section is intended to give visitors a simple overview of the product category without providing medical advice, treatment guidance, dosage guidance, or usage instruction. For product-specific details, availability, or additional information, please contact us on Telegram.

Observations are provided for general educational and research reference only.

Complementary strategies for general wellness and consistency.

General product handling information for educational and research reference only.

For product-specific information, availability, or additional support, please contact us on Telegram.

Why Vitality Labs?

Important Note: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment.

Explore related research dosage protocols and background reading for BPC-157 + TB-500.

FDA

— Bremelanotide (Vyleesi) prescribing information: dosing, safety, and use limitations

NCBI Bookshelf (LiverTox)

— Bremelanotide: mechanism, clinical use, and hepatic safety profile

PMC

— Bremelanotide for treatment of female hypoactive sexual desire disorder: clinical trial review

Mayo Clinic

— Bremelanotide (subcutaneous route): side effects, dosage, and precautions

PubMed

— Evaluation of Melanotan-II: pilot phase-I clinical study on safety and efficacy

RxList

— Melanotan-II: uses, side effects, dosing, and precautions overview

Bachem

— Handling and storage guidelines for peptides: lyophilized and reconstituted stability

NCBI Bookshelf (WHO)

— Best practices for injections and related procedures: asepsis and technique

Healthline

— Subcutaneous injection: technique, sites, and step-by-step guidance

CDC

— Vaccine administration: subcutaneous injection angle and site selection

PMC

— Subcutaneous drug injection: pharmacologic considerations and clinical review

Expert Opinion on Biological Therapy (PubMed)

— Thymosin beta-4 and its role in wound healing

CDC

— Vaccine administration: subcutaneous route (angle/site; no aspiration)

PMC

— Subcutaneous drug injection: pharmacologic considerations and clinical review

Contact on Telegram Peptides

— BPC-157 + TB-500 (10 mg blend) product page (quality and batch documentation)